Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors
Hlavní autoři: | Ghazaly, E, Woodcock, V, Spilipoulou, P, Spiers, L, Moschandreas, J, Griffiths, L, Gnanaranjan, C, Harrison, D, Evans, T, Blagden, S |
---|---|
Médium: | Conference item |
Vydáno: |
Oxford University Press
2017
|
Podobné jednotky
-
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
Autor: Pavlina Spiliopoulou, a další
Vydáno: (2024-04-01) -
3373 Modulation of Hedgehog Signaling Alters Immune Infiltration in Pancreatic Cancer
Autor: Nina Steele, a další
Vydáno: (2019-03-01) -
Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
Autor: Longfei Zhang, a další
Vydáno: (2022-03-01) -
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
Autor: Blagden, SP, a další
Vydáno: (2018) -
Pharmacodynamics, chiral pharmacokinetics and PK–PD modelling of ketoprofen in the goat
Autor: Abdul Kadir, Arifah, a další
Vydáno: (2003)